Back to companies

Fresenius Kabi AG: Premium Databases

Fresenius Kabi AG Marketed Drugs

Understand Fresenius Kabi AG’s commercialized product portfolio to stay one step ahead of the market.

A sample of Fresenius Kabi AG Marketed Drugs data

Drug Name Generic Name Brand Name Company Name Therapy Area Indication Development Stage Drug Geography
Showing 3 of 290+ results. Subscribe to unlock more.
Lorem Lorem Lorem Lorem Lorem Lorem Planned Lorem
lacosamide lacosamide Lacosamide Fresenius Kabi USA LLC Central Nervous System Partial Seizure Marketed United States
lacosamide lacosamide Lacosamide Fresenius Kabi Ltd Central Nervous System Epilepsy Marketed United Kingdom
lacosamide lacosamide Lacosamide Fresenius Kabi Ltd Central Nervous System Generalized Seizures Marketed United Kingdom
Marketed Drugs

Feature

Marketed Drugs is an integrated platform that provides interactive, comprehensive, and analytical competitive intelligence of Marketed Pharmaceutical Drug information.

Benefit

Marketed Drugs covers an extensive number of therapy areas and indications across 23 countries. Marketed Drug profiles provide a comprehensive breakdown of information spanning across Drug Details, Marketed Drug Overview (Lifecycle Management, Safety Details and Efficacy Details), Marketing Information (Regulatory Information), Clinical Trials, Sales and Consensus Forecast and Net Present Value.

Keep up-to-date on new Pipeline drug developments and market approvals. Competitive analysis of Marketed drugs.

Value

Marketed Drug data is used prominently to generate a range of premium analytical reports offering unique insight. Seamless integration makes in depth investigation of drugs extremely simple.

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer